TARA filing — read by section

UNITED STATES 
 
 SECURITIES AND EXCHANGE COMMISSION 
 
 WASHINGTON, DC 20549 
 
 FORM 10-Q 
 
 (Mark One) 
 
 ☒ QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
 
 For the quarterly period ended June 30, 2024 
 
 or 
 
 ☐ TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
 
 For the transition period from 
to 
 
 Commission
File Number: 001-36694 
 
 Protara Therapeutics, Inc. 
 
 (Exact name
of registrant as specified in its charter) 
 
 Delaware 20-4580525 
 (State or other jurisdiction of

incorporation or organization) (I.R.S. Employer

Identification No.) 
 
 345 Park Avenue South 
 
 3 rd Floor 
 
 New York , NY 
 
 (Address of principal executive offices) 
 
 10010 
 
 (Zip Code) 
 
 (646) 844-0337 
 
 (Registrant’s telephone number, including
area code) 
 
 Securities registered pursuant to Section 12(b)
of the Act:
 
 Title of each class Trading Symbol(s) Name of each exchange on which registered 
 Common Stock, $0.001 par value per share TARA The Nasdaq Capital Market 
 
 Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
 
 Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 
☒ No ☐
 
 Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
 Large accelerated filer ☐ Accelerated filer ☐ 
 Non-accelerated filer ☒ Smaller reporting company ☒ 
 Emerging growth company ☐ 
 
 If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ 
 
 As
of August 1, 2024 there were 20,629,772 shares of the registrant’s
common stock, par value $0.001 per share, outstanding. 
 
 TABLE OF CONTENTS 
 
 Page 

 PART I – FINANCIAL INFORMATION 
 1 

 Item 1. 
 Condensed Consolidated Financial Statements 
 1 

 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (unaudited) 
 1 

 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2024 and 2023 (unaudited) 
 2 

 Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited) 
 3 

 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (unaudited) 
 4 

 Notes to Unaudited Condensed Consolidated Financial Statements 
 5 

 Item 2. 
 Management’s Discussion and Analysis of Financial Condition and Results of Operations 
 17 

 Item 3. 
 Quantitative and Qualitative Disclosures About Market Risk 
 25 

 Item 4. 
 Controls and Procedures 
 25 

 PART II – OTHER INFORMATION 
 26 

 Item 1. 
 Legal Proceedings 
 26 

 Item 1A. 
 Risk Factors 
 26 

 Item 2. 
 Unregistered Sales of Equity Securities and Use of Proceeds 
 26 

 Item 3. 
 Defaults Upon Senior Securities 
 26 

 Item 4. 
 Mine Safety Disclosures 
 26 

 Item 5. 
 Other Information 
 26 

 Item 6. 
 Exhibits 
 27 

 EXHIBIT INDEX 
 27 

 SIGNATURES 
 29 

 i 

 CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS 
 
 This Quarterly Report on
Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and
financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking
statements. In some cases, you can identify these forward-looking statements by terminology such as “believes,” “expects,”
“potential,” “continues,” “may,” “will,” “should,” “seek,” “approximately,”
“predict,” “intend,” “plans,” “estimates,” “anticipates” or the negative version
of these terms or other comparable terminology. These forward-looking statements are subject to various risks and uncertainties. Accordingly,
there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these
statements.
 
 These forward-looking statements include,
but are not limited to, statements about:
 
 ● 
 estimates regarding our financial performance, including future revenue, expenses and capital requirements; 

 ● 
 our expected cash position and ability to obtain financing in the future on satisfactory terms or at all; 

 ● 
 expectations regarding our plans to research, develop and commercialize our current and future product candidates, including TARA-002, and Intravenous, or IV, Choline Chloride; 

 ● 
 expectations regarding the safety and efficacy of our product candidates; 

 ● 
 expectations regarding the timing, costs and outcomes of our planned clinical trials; 

 ● 
 expectations regarding potential market size; 

 ● 
 expectations regarding the timing of the availability of data from our clinical trials; 

 ● 
 expectations regarding the clinical utility, potential benefits and market acceptance of our product candidates; 

 ● 
 expectations regarding our commercialization, marketing and manufacturing capabilities and strategy; 

 ● 
 the implementation of our business model, strategic plans for our business, product candidates and technology; 

 ● 
 expectations regarding our ability to identify additional products or product candidates with significant commercial potential; 

 ii 

 ● 
 developments and projections relating to our competitors and industry; 

 ● 
 our ability to acquire, license and invest in businesses, technologies, product candidates and products; 

 ● 
 our ability to remain listed on the Nasdaq Capital Market, or Nasdaq; 

 ● 
 the impact of government laws and regulations; 

 ● 
 costs and outcomes relating to any disputes, governmental inquiries or investigations, regulatory proceedings, legal proceedings or litigation; 

 ● 
 our ability to attract and retain key personnel to manage our business effectively; 

 ● 
 our ability to prevent system failures, data breaches or violations of data protection laws; 

 ● 
 the timing or likelihood of regulatory filings and approvals; 

 ● 
 our ability to protect our intellectual property position; and 

 ● 
 the impact of general U.S., foreign and global economic, industry, market, regulatory, political or public health conditions. 

 All forward-looking statements
in this Quarterly Report on Form 10-Q involve known and unknown risks, uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these
forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other
things, the risk factors set forth below in Part II, Item 1A, Risk Factors , and elsewhere in this Quarterly Report on Form 10-Q.
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included
in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information
becomes available in the future.
 
 This Quarterly Report on
Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain
medical conditions, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical
conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject
to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.
Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies
and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data
and similar sources.
 
 iii 

 PART I – FINANCIAL INFORMATION 
 
 Item 1. Financial Statements 
 
 PROTARA THERAPEUTICS, INC. AND SUBSIDIARIES 
 
 Unaudited Condensed Consolidated Balance Sheets 
 
 (in thousands, except share and per share data) 
 
 As of 

 June 30,
 2024 
 December 31, 
 2023 

 Assets 
 
 Current assets: 
 
 Cash and cash equivalents 
 $ 89,581 
 $ 39,586 

 Marketable debt securities 
 -
 
 25,994 

 Prepaid expenses and other current assets 
 2,633 
 3,125 

 Total current assets 
 92,214 
 68,705 

 Restricted cash, non-current 
 745 
 745 

 Property and equipment, net 
 1,185 
 1,296 

 Operating lease right-of-use asset 
 4,768 
 5,264 

 Other assets 
 2,735 
 2,944 

 Total assets 
 $ 101,647 
 $ 78,954 

 Liabilities and Stockholders’ Equity 
 
 Current liabilities: 
 
 Accounts payable 
 $ 1,385 
 $ 2,434 

 Accrued expenses and other current liabilities 
 3,228 
 2,732 

 Operating lease liability 
 1,035 
 983 

 Total current liabilities 
 5,648 
 6,149 

 Operating lease liability, non-current 
 3,949 
 4,484 

 Total liabilities 
 9,597 
 10,633 

 Commitments and contingencies (Note 9) 
 
 Stockholders’ Equity: 
 
 Preferred stock, $ 0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 shares authorized at June 30, 2024 and December 31, 2023, 7,991 shares issued and outstanding as of June 30, 2024 and December 31, 2023. 
 -
 
 -
 
 Common stock, $ 0.001 par value, authorized 100,000,000 shares: Common stock, 20,629,772 and 11,364,903 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. 
 21 
 11 

 Additional paid-in capital 
 313,021 
 268,725 

 Accumulated deficit 
 ( 220,992 ) 
 ( 200,384 ) 

 Accumulated other comprehensive income (loss) 
 -
 
 ( 31 ) 

 Total stockholders’ equity 
 92,050 
 68,321 

 Total liabilities and stockholders’ equity 
 $ 101,647 
 $ 78,954 

 The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
 
 1 

 PROTARA THERAPEUTICS, INC. AND SUBSIDIARIES 
 
 Unaudited Condensed Consolidated Statements
of Operations and Comprehensive Loss 
 
 (in thousands, except share and per share data) 
 
 For the Three Months Ended
 June 30, 
 For the Six Months Ended 
 June 30, 

 2024 
 2023 
 2024 
 2023 

 Operating expenses: 
 
 Research and development 
 $ 6,387 
 $ 7,247 
 $ 14,135 
 $ 12,390 

 General and administrative 
 4,274 
 4,893 
 8,377 
 9,482 

 Total operating expenses 
 10,661 
 12,140 
 22,512 
 21,872 

 Loss from operations 
 ( 10,661 ) 
 ( 12,140 ) 
 ( 22,512 ) 
 ( 21,872 ) 

 Other income (expense), net: 
 
 Interest and investment income 
 1,148 
 846 
 1,904 
 1,533 

 Other income (expense), net 
 1,148 
 846 
 1,904 
 1,533 

 Net income (loss) 
 $ ( 9,513 ) 
 $ ( 11,294 ) 
 $ ( 20,608 ) 
 $ ( 20,339 ) 

 Net income (loss) per share attributable to common stockholders, basic and diluted
 
 $ ( 0.45 ) 
 $ ( 1.00 ) 
 $ ( 1.26 ) 
 $ ( 1.80 ) 

 Weighted-average shares outstanding, basic and diluted
 
 21,233,163 
 11,307,842 
 16,327,056 
 11,305,867 

 Other comprehensive income (loss): 
 
 Net unrealized gain (loss) on marketable debt securities 
 1 
 133 
 31 
 352 

 Other comprehensive income (loss) 
 1 
 133 
 31 
 352 

 Comprehensive income (loss) 
 $ ( 9,512 ) 
 $ ( 11,161 ) 
 $ ( 20,577 ) 
 $ ( 19,987 ) 

 The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
 
 2 

 PROTARA
THERAPEUTICS, INC. AND SUBSIDIARIES 
 
 Unaudited Condensed Consolidated Statements
of Changes in Stockholders’ Equity 
 
 (in thousands, except share and per share data) 
 
 Series 1
 Convertible
 Preferred Stock 
 Common Stock 
 Additional 
 Paid-in 
 Accumulated 
 Accumulated 
 Other
 Comprehensive 
 Total 
 Stockholders’ 

 Shares 
 Amount 
 Shares 
 Amount 
 Capital 
 Deficit 
 Income (Loss) 
 Equity 

 Balance at December 31, 2022 
 8,027 
 $ -
 
 11,267,389 
 $ 11 
 $ 262,724 
 $ ( 159,964 ) 
 $ ( 688 ) 
 $ 102,083 

 Issuance of common stock upon settlement of restricted stock units 
 -
 
 -
 
 39,364 
 -
 
 ( 64 ) 
 -
 
 -
 
 ( 64 ) 

 Stock-based compensation - restricted stock units 
 - 
 -
 
 - 
 -
 
 314 
 -
 
 -
 
 314 

 Stock-based compensation - stock options 
 - 
 -
 
 - 
 -
 
 1,261 
 -
 
 -
 
 1,261 

 Unrealized gain (loss) on marketable debt securities 
 - 
 -
 
 - 
 -
 
 -
 
 -
 
 219 
 219 

 Net income (loss) 
 - 
 -
 
 - 
 -
 
 -
 
 ( 9,045 ) 
 -
 
 ( 9,045 ) 

 Balance at March 31, 2023 
 8,027 
 $ -
 
 11,306,753 
 $ 11 
 $ 264,235 
 $ ( 169,009 ) 
 $ ( 469 ) 
 $ 94,768 

 Issuance of common stock upon settlement of restricted stock units 
 -
 
 -
 
 1,209 
 -
 
 -
 
 -
 
 -
 
 -
 
 Stock-based compensation - restricted stock units 
 - 
 -
 
 - 
 -
 
 326 
 -
 
 -
 
 326 

 Stock-based compensation - stock options 
 - 
 -
 
 - 
 -
 
 1,292 
 -
 
 -
 
 1,292 

 Unrealized gain (loss) on marketable debt securities 
 - 
 -
 
 - 
 -
 
 -
 
 -
 
 133 
 133 

 Net income (loss) 
 - 
 -
 
 - 
 -
 
 -
 
 ( 11,294 ) 
 -
 
 ( 11,294 ) 

 Balance at June 30, 2023 
 8,027 
 $ -
 
 11,307,962 
 $ 11 
 $ 265,853 
 $ ( 180,303 ) 
 $ ( 336 ) 
 $ 85,225 

 Balance at December 31, 2023 
 7,991 
 $ -
 
 11,364,903 
 $ 11 
 $ 268,725 
 $ ( 200,384 ) 
 $ ( 31 ) 
 $ 68,321 

 Issuance of common stock upon settlement of restricted stock units 
 -
 
 -
 
 68,934 
 -
 
 ( 76 ) 
 -
 
 -
 
 ( 76 ) 

 Stock-based compensation - restricted stock units 
 - 
 -
 
 - 
 -
 
 151 
 -
 
 -
 
 151 

 Stock-based compensation - stock options 
 - 
 -
 
 - 
 -
 
 1,075 
 -
 
 -
 
 1,075 

 Unrealized gain (loss) on marketable debt securities 
 - 
 -
 
 - 
 -
 
 -
 
 -
 
 30 
 30 

 Net income (loss) 
 - 
 -
 
 - 
 -
 
 -
 
 ( 11,095 ) 
 -
 
 ( 11,095 ) 

 Balance at March 31, 2024 
 7,991 
 $ -
 
 11,433,837 
 $ 11 
 $ 269,875 
 $ ( 211,479 ) 
 $ ( 1 ) 
 $ 58,406 

 Issuance of common stock, pre-funded warrants and warrants from private placement, net of offering costs of $ 3,034 
 
 9,143,380 
 10 
 41,954 
 
 41,964 

 Issuance of common stock upon settlement of restricted stock units 
 -
 
 -
 
 4,975 
 -
 
 ( 7 ) 
 -
 
 -
 
 ( 7 ) 

 Issuance of common stock upon exercise of stock options 
 -
 
 -
 
 47,580 
 --
 
 135 
 -
 
 -
 
 135 

 Stock-based compensation - restricted stock units 
 - 
 -
 
 - 
 -
 
 111 
 -
 
 -
 
 111 

 Stock-based compensation - stock options 
 - 
 -
 
 - 
 -
 
 953 
 -
 
 -
 
 953 

 Unrealized gain (loss) on marketable debt securities 
 - 
 -
 
 - 
 -
 
 -
 
 -
 
 1 
 1 

 Net income (loss) 
 - 
 -
 
 - 
 -
 
 -
 
 ( 9,513 ) 
 -
 
 ( 9,513 ) 

 Balance at June 30, 2024 
 7,991 
 $ -
 
 20,629,772 
 $ 21 
 $ 313,021 
 $ ( 220,992 ) 
 $ -
 
 $ 92,050 

 The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
 
 3 

 PROTARA THERAPEUTICS, INC. AND SUBSIDIARIES 
 
 Unaudited Condensed Consolidated Statements
of Cash Flows 
 
 (in thousands) 
 
 For the Six Months Ended 
 June 30, 

 2024 
 2023 

 Cash flows used in operating activities: 
 
 Net income (loss) 
 $ ( 20,608 ) 
 $ ( 20,339 ) 

 Adjustments to reconcile net income (loss) to net cash used in operating activities: 
 
 Stock-based compensation 
 2,290 
 3,193 

 Operating lease right-of-use asset 
 496 
 683 

 Depreciation 
 166 
 155 

 Amortization of premium (Accretion of discount) on marketable debt securities 
 ( 75 ) 
 ( 204 ) 

 Changes in operating assets and liabilities: 
 
 Prepaid expenses and other current assets 
 492 
 ( 2,044 ) 

 Other assets 
 209 
 ( 2,237 ) 

 Accounts payable 
 ( 1,049 ) 
 266 

 Accrued expenses and other current liabilities 
 496 
 ( 1,106 ) 

 Operating lease liabilities 
 ( 483 ) 
 ( 663 ) 

 Net cash provided by/(used in) operating activities 
 ( 18,066 ) 
 ( 22,296 ) 

 Cash flows from investing activities: 
 
 Purchase of marketable debt securities 
 -
 
 ( 12,186 ) 

 Proceeds from maturity and redemption of marketable debt securities 
 26,100 
 44,405 

 Purchase of property and equipment 
 ( 55 ) 
 ( 8 ) 

 Net cash provided by/(used in) investing activities 
 26,045 
 32,211 

 Cash flows from financing activities: 
 
 Proceeds from private placement, net of offering costs of $ 3,034 
 41,964 
 - 

 Proceeds from exercise of stock options 
 135 
 - 

 Taxes paid related to net share settlement of restricted stock units 
 ( 83 ) 
 ( 64 ) 

 Net cash provided by/(used in) financing activities 
 42,016 
 ( 64 ) 

 Net increase (decrease) in cash and cash equivalents and restricted cash 
 49,995 
 9,851 

 Cash and cash equivalents and restricted cash - beginning of year 
 40,331 
 24,872 

 Cash and cash equivalents and restricted cash - end of period 
 $ 90,326 
 $ 34,723 

 Reconciliation of cash and cash equivalents and restricted cash to the condensed consolidated balance sheets: 
 
 Cash and cash equivalents 
 $ 89,581 
 $ 33,978 

 Restricted cash, non-current 
 745 
 745 

 Cash and cash equivalents and restricted cash 
 $ 90,326 
 $ 34,723 

 The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
 
 4 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 1.
Organization and Nature of the Business 

 Overview 

 Protara Therapeutics, Inc.,
and its consolidated subsidiaries (“Protara” or the “Company”), is a clinical-stage biopharmaceutical company
committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includes two
development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder
cancer, or NMIBC, and lymphatic malformations, or LMs. Additionally, the Company’s portfolio includes Intravenous, or IV, Choline
Chloride, an investigational phospholipid substrate replacement therapy in development for patients receiving parenteral nutrition, or
PN.

 Liquidity and Capital Resources 

 The Company is in the business
of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs
in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans.

 The Company believes that
its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least twelve months from
the date of issuance of these unaudited condensed consolidated financial statements.
 
 2.
Summary of Significant Accounting Policies 

 The Company’s significant
accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission, or SEC, on
March 13, 2024. Except as reflected below, there were no changes to the Company’s significant accounting policies as described in
the Annual Report on Form 10-K. Reflected in this note are updates to accounting policies, including the impact of the adoption of new
policies.

 Basis of Presentation 
 
 The accompanying condensed
consolidated financial statements and the related disclosures as of June 30, 2024 and for the three and six months ended June 30, 2024
and 2023 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP,
and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and
footnotes required by GAAP for complete financial statements. These interim condensed consolidated financial statements should be read
in conjunction with the 2023 and 2022 audited consolidated financial statements and notes included in the Annual Report on Form 10-K.
The December 31, 2023 consolidated balance sheet included herein was derived from the audited financial statements as of that date but
does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the
condensed consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the
fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, 2024
and 2023. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year
ending December 31, 2024 or any other interim period or future year or period.
 
 5 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 Principles of Consolidation 
 
 The condensed consolidated
financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions
have been eliminated in the accompanying condensed consolidated financial statements.
 
 Use of Estimates 
 
 The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities,
revenues, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements.
Significant items subject to such estimates include but are not limited to research and development accruals as well as contingencies.
 
 On an ongoing basis, the
Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions
believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected
in the financial statements of the period in which the change becomes evident.
 
 Concentrations of Credit Risk 
 
 Financial instruments, which
potentially subject the Company to concentrations of credit risk, consists principally of cash and cash equivalents, restricted cash and
investments in marketable debt securities.
 
 The Company currently invests
its excess cash primarily in money market funds and high quality investment grade marketable debt securities of corporations. The Company
has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal
and liquidity.
 
 Net Income (Loss) Per Share Attributable
to Common Stockholders 
 
 Basic net income (loss) per
share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common
stock outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) attributable to common
stockholders by the weighted-average number of shares of common stock outstanding during the period plus, if dilutive, the common equivalent
shares for the period from unvested restricted common stock, outstanding stock options, potential shares issuable under the 2024 ESPP,
the conversion of preferred stock, and the exercise of Common Warrants issued in connection with the 2024 Private Placement, discussed
further in Note 10. Stockholders’ Equity.
 
 Given the nominal exercise price associated with the Company’s
pre-funded warrants, or the Pre-Funded Warrants, issued in connection with the 2024 Private Placement (discussed further in Note 10. Stockholders’
Equity) such Pre-Funded Warrants are included in the calculation of basic and diluted net income (loss) per share. The exercise price
per warrant is deemed nonsubstantive when compared to the market value of the underlying common shares. The weighted average impact of
the 1,700,000 unexercised Pre-Funded Warrants as of June 30, 2024 was included in the Company’s calculation of basic and diluted
loss per share.
 
 Warrants 
 
 The Company accounts for
warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms
and applicable authoritative guidance in the Financial Accounting Standards Board, or the FASB, Accounting Standards Codification, or
ASC, 480, Distinguishing Liabilities from Equity , or ASC 480, and ASC 815, Derivatives and Hedging , or ASC 815. The assessment
considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants
are indexed to the Company’s own stock and whether the warrant holders could potentially require “net cash settlement”
in a circumstance outside of the Company’s control, among other conditions for equity classification. Finally, the Company determines
if the warrants meet the definition of a derivative based on their contractual terms. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
 
 For issued or modified warrants
that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in
capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and at each balance sheet date thereafter. Changes in
the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the consolidated statements of
operations. The Company also evaluates if changes in contractual terms or other considerations would result in the reclassification of
outstanding warrants from liabilities to stockholders’ equity (or vice versa).
 
 The fair market value of the warrants may be estimated using a Black-Scholes
option-pricing model or potentially more complex valuation models depending on the nature of the contractual terms. 
 
 6 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 Recent Accounting Pronouncements Not Yet Adopted 
 
 In November 2023, the FASB issued ASU 2023-07 – Improvements to Reportable Segment Disclosures, which enhances the
disclosures required for reportable segments in annual and interim consolidated financial statements, including additional, more detailed
information about a reportable segment’s expenses. The standard is effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024. Early adoption is available. The Company is still evaluating
the full extent of the potential impact of the adoption of ASU 2023-07, but believes it will not have a material impact on its consolidated
financial statements and disclosures.
 
 In December 2023, the FASB
issued ASU 2023-09 – Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax
disclosures. The standard is effective for public companies for annual periods beginning after December 15, 2024. Early adoption is available.
The Company is still evaluating the full extent of the potential impact of the adoption of ASU 2023-09, but believes it will not have
a material impact on its consolidated financial statements and disclosures.
 
 Subsequent Events 
 
 The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued.
The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.
 
 3.
Fair Value of Financial Instruments 

 The Company measures certain
financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or
the most advantageous market.

 Inputs used in the valuation
techniques to derive fair values are classified based on a three-level hierarchy, as follows:

 ● 
 Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. 

 ● 
 Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. 

 ● 
 Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. 

 The following tables present
the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair
value hierarchy of valuation techniques it utilizes to determine such fair value: 

 As of June 30, 2024 

 Level 1 
 Level 2 
 Level 3 
 Total 

 Cash equivalents: 
 
 Money market funds (a) 
 $ 89,079 
 $ -
 
 $ -
 
 $ 89,079 

 Restricted cash, non-current: 
 
 Money market funds (b) 
 745 
 -
 
 -
 
 745 

 Total 
 $ 89,824 
 $ -
 
 $ -
 
 $ 89,824 

 7 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 As of December 31, 2023 

 Level 1 
 Level 2 
 Level 3 
 Total 

 Cash equivalents: 
 
 Money market funds (a) 
 $ 39,031 
 $ -
 
 $ -
 
 $ 39,031 

 Restricted cash, non-current: 
 
 Money market funds (b) 
 745 
 -
 
 -
 
 745 

 Marketable debt securities: 
 
 Corporate bonds (c) 
 -
 
 23,495 
 -
 
 23,495 

 Agency bonds (c) 
 -
 
 2,499 
 -
 
 2,499 

 Total 
 $ 39,776 
 $ 25,994 
 $ -
 
 $ 65,770 

 (a) Money market funds and bonds with original maturities of 90 days or less are included within Cash and cash equivalents in the condensed consolidated balance sheets. 
 
 (b) Restricted money market funds are included within Restricted cash, non-current in the condensed consolidated balance sheets. 
 
 (c) Bonds with original maturities greater than 90 days are included within Marketable debt securities in the condensed consolidated balance sheets and classified as current or non-current based upon whether the maturity of the financial asset is less than or greater than 12 months. 
 
 Money market funds are classified
as Level 1 within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate and agency bonds
classified as Level 2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants
provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services
and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment,
pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices
and market transactions in comparable investments and various relationships between investments. There were no transfers of financial
instruments among Level 1, Level 2, and Level 3 during the period presented.

 Cash and cash equivalents,
prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities at June 30, 2024 and December
31, 2023 are carried at amounts that approximate fair value due to their short-term maturities.
 
 4.
Marketable Debt Securities 

 The Company did not hold
any marketable debt securities as of June 30, 2024. Marketable debt securities, all of which were classified as available for sale as
of December 31, 2023, consist of the following: 

 As of December 31, 2023 

 Amortized
 Cost 
 Unrealized
 Gains 
 Unrealized
 Losses 
 Estimated 
 Fair Value 

 Corporate bonds - presented in marketable debt securities 
 $ 23,525 
 $ -
 
 $ ( 30 ) 
 $ 23,495 

 Agency bonds - presented in marketable debt securities 
 2,500 
 -
 
 ( 1 ) 
 2,499 

 Total 
 $ 26,025 
 $ -
 
 $ ( 31 ) 
 $ 25,994 

 For the three and six months
ended June 30, 2024 and 2023 there were no realized gains or losses. Gains, if any, would be included in investment income within the
condensed consolidated statements of operations and comprehensive loss.

 The Company has recorded
the securities at fair value in its condensed consolidated balance sheets and unrealized gains and losses are reported as a component
of accumulated other comprehensive income (loss). The amount of realized gains and losses reclassified into earnings are based on the
specific identification of the securities sold or securities that reached maturity date. The amount of realized gains and losses reclassified
into earnings have not been material to the Company’s condensed consolidated statements of operations and comprehensive loss.
 
 8 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 At the time of purchase,
the Company determines the appropriate classification of investments based upon its intent with regard to such investments. The Company
classifies investments in marketable debt securities with remaining maturities when purchased of greater than three months as available-for-sale.
Investments with a remaining maturity date greater than one year are classified as non-current. There were no sales of marketable
debt securities in the periods presented.

 Credit Losses 

 Securities with an amortized
cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit
losses. For the period ended June 30, 2024, no securities were held and as such it was determined that there was no expected credit loss.

 Marketable debt securities
in a loss position consist of the following: 

 As of December 31, 2023 

 In Continuous Loss Position
 Less Than 12 Months 
 In Continuous Loss Position
 Greater Than 12 Months 
 Total 

 Estimated
 Fair Value 
 Unrealized
 Losses 
 Estimated
 Fair Value 
 Unrealized
 Losses 
 Estimated
 Fair Value 
 Unrealized
 Losses 

 Corporate bonds – presented in marketable debt securities 
 $ 19,498 
 $ ( 27 ) 
 $ 3,997 
 $ ( 3 ) 
 $ 23,495 
 $ ( 30 ) 

 Agency bonds – presented in marketable debt securities 
 2,499 
 ( 1 ) 
 -
 
 -
 
 2,499 
 ( 1 ) 

 Total 
 $ 21,997 
 $ ( 28 ) 
 $ 3,997 
 $ ( 3 ) 
 $ 25,994 
 $ ( 31 ) 

 Investment Income 

 Interest and investment income consist of the
following: 

 For the Three Months Ended June 30, 
 
 For the Six Months Ended 
 June 30, 
 
 2024 
 2023 
 2024 
 2023 

 Interest income 
 $ 1,130 
 $ 710 
 $ 1,809 
 $ 1,315 

 Dividend income 
 11 
 4 
 20 
 4 

 Accretion of discount (Amortization of premium), net 
 7 
 132 
 75 
 214 

 Total interest and investment income 
 $ 1,148 
 $ 846 
 $ 1,904 
 $ 1,533 

 5.
Prepaid Expenses and Other Current Assets 

 Prepaid expenses and other
current assets consist of the following: 

 As of 

 June 30, 2024 
 December 31, 2023 

 Prepaid research and development 
 $ 1,574 
 $ 1,957 

 Prepaid insurance 
 460 
 659 

 Prepaid retention bonuses 
 200 
 -
 
 Prepaid software 
 122 
 67 

 Accrued interest on marketable debt securities 
 -
 
 242 

 Other prepaid expenses 
 273 
 163 

 Other current assets 
 4 
 37 

 Total 
 $ 2,633 
 $ 3,125 

 9 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 6.
Other Assets 

 Other assets consist of the following: 

 As of 

 June 30, 2024 
 December, 31, 2023 

 Prepaid research and development, non-current 
 $ 2,580 
 $ 2,661 

 Prepaid insurance, non-current 
 136 
 272 

 Other non-current assets 
 19 
 11 

 Total 
 $ 2,735 
 $ 2,944 

 7.
Accrued Expenses and Other Current Liabilities 

 Accrued expenses and other
current liabilities consist of the following: 

 As of 

 June 30, 2024 
 December 31, 2023 

 Research and development costs 
 2,108 
 440 

 Employee costs 
 999 
 2,112 

 Other expenses 
 121 
 180 

 Total 
 $ 3,228 
 $ 2,732 

 8.
Leases 

 Operating leases 

 Leases classified as operating
leases are included in operating lease right-of use, or ROU, assets, operating lease liabilities and operating lease liabilities, non-current,
in the Company’s condensed consolidated balance sheets. Cash paid for operating lease liabilities was $ 663 during each of the six
months ended June 30, 2024 and 2023.

 Lease expense consist of
the following: 

 For the Three Months Ended 
 June 30, 
 
 For the Six Months Ended 
 June 30, 
 
 2024 
 2023 
 2024 
 2023 

 Operating lease expense 
 $ 338 
 $ 342 
 $ 676 
 $ 683 

 Total 
 $ 338 
 $ 342 
 $ 676 
 $ 683 

 Variable lease expenses for
the three and six months ended June 30, 2024 were $ 26 and $ 46 , respectively. Variable lease expenses for the three and six months ended
June 30, 2023 were not material.
 
 10 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 The weighted-average remaining
lease term and the weighted average discount rate for operating leases were: 

 As of
 June 30, 
 2024 
 Weighted-average discount rate 7.0 % 
 Weighted-average remaining lease term – operating lease (in months) 49 
 
 As of June 30, 2024, the
expected annual minimum lease payments of the Company’s operating lease liabilities were as follows: 

 For Years Ending December 31, 
 Operating
 Lease
 Payments 

 2024 (excluding the six months ended June 30, 2024) 
 $ 663 

 2025 
 1,395 

 2026 
 1,429 

 2027 
 1,429 

 2028 
 718 

 Thereafter 
 87 

 Total operating lease payments 
 5,721 

 Less: imputed interest 
 ( 737 ) 

 Present value of future minimum lease payments 
 $ 4,984 

 9.
Commitments and Contingencies 

 Commitments 

 The Company has commitments
under certain license and collaboration agreements, lease agreements, and employment agreements. Commitments under certain license agreements
primarily include annual payments, payments upon the achievement of certain milestones, and royalty payments based on net sales of licensed
products. Commitments under lease agreements consist of future minimum lease payments for operating leases which are further described
in Note 8 of this Quarterly Report on Form 10-Q.

 Contingencies 

 From time to time, the Company
may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of
the opinion that the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company
or the results of its operations.

 In the normal course of business,
the Company enters into contracts in which it makes representations and warranties regarding the performance of its services and that
its services will not infringe on third-party intellectual rights. There have been no significant events related to such representations
and warranties in which the Company believes the outcome could result in losses or penalties in the future.
 
 10 .
 Stockholders’ Equity 

 Common Stock 

 As of June 30, 2024 and December
31, 2023, the Company had 100,000,000 shares of common stock authorized for issuance, $ 0.001 par value per share, of which 20,629,772 
and 11,364,903 shares were issued and outstanding, respectively.

 The holders of the Company’s
common stock are entitled to one vote per share.

 Preferred Stock 

 As of June 30, 2024 and December
31, 2023, the Company had 10,000,000 shares of preferred stock authorized for issuance, $ 0.001 par value per share, of which 8,028 shares
of Series 1 Convertible Preferred Stock were authorized for issuance and 7,991 shares were issued and outstanding as of June 30, 2024
and December 31, 2023. Each share of Series 1 Convertible Preferred Stock is convertible into approximately 1,000 shares of common stock,
at a conversion price initially equal to approximately $ 7.01 per common share, subject to certain adjustments as described in the certificate
of designation of preferences, rights and limitations of Series 1 Convertible Preferred Stock.
 
 11 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 During August 2023, approximately
 36 shares of Series 1 Convertible Preferred Stock were converted into 35,823 shares of common stock.

 The holders of Series 1 Convertible
Preferred Stock are not entitled to vote.

 April
2024 Equity Financing 

 On
April 5, 2024, the Company entered into a subscription agreement with
certain purchasers, or the Purchasers, pursuant to which the Company agreed to sell and issue to the Purchasers, in a private placement,
or the 2024 Private Placement, an aggregate of 9,143,380 shares of the Company’s common stock, or the Shares, and, for certain
purchasers, pre-funded warrants, or the Pre-Funded Warrants, to purchase an aggregate of 1,700,000 shares of the Company’s common
stock. In each case, the Shares or Pre-Funded Warrants were issued with warrants, or the Common Warrants, to purchase an aggregate of
up to 10,843,380 shares of the Company’s common stock. Each Share, along with its attached Common Warrant, had a purchase price
of $ 4.15 , and each Pre-Funded Warrant, along with its attached Common Warrant, had a purchase price of $ 4.149 . The closing date of the
2024 Private Placement was April 10, 2024. The 2024 Private Placement resulted in gross proceeds
of approximately $ 44,998 and net proceeds of approximately $ 42,964 , reflecting approximately $ 3,034 of placement agent’s fees,
legal costs and other expenses connected with the transaction. 

 The Pre-Funded Warrants are
exercisable at any time after April 10, 2024, at an exercise price of $ 0.001 per share. The Common Warrants are exercisable on or prior
to the earlier of (i) April 10, 2027 and (ii) 90 days after the public announcement that the Company has demonstrated a six-month complete
response rate of minimum 42% from at least 25 Bacillus Calmette-Guérin (BCG)-Unresponsive patients in the ADVANCED-2 (Cohort B)
clinical trial, at an exercise price of $ 5.25 per share.

 The Pre-Funded Warrants and
the Common Warrants are exercisable so long as the aggregate number of shares of the Company’s common stock beneficially owned by
the holder (together with its affiliates) would not exceed 4.99 % of the number of shares of the Company’s common stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such Pre-Funded
Warrant or Common Warrant, as applicable. Such percentage may be increased or decreased to any number not in excess of 19.99 % at the holder’s
election upon notice to the Company, any such increase not to take effect until the sixty-first day after notice to the Company.

 Both the Pre-Funded Warrants
and the Common Warrants contain standard adjustments to the exercise price, inclusive of stock splits, stock dividends and pro rata distributions
and contain customary terms regarding the treatment of such Pre-Funded Warrants or Common Warrants in the event of a fundamental transaction,
which include but are not limited to a merger or consolidation involving the Company, a sale of all or substantially all of the assets
of the Company or a business combination resulting in any person acquiring more than 50 % of the outstanding shares of Common Stock of
the Company.

 The
Company concluded that the Pre-Funded Warrants and Common Warrants met the requirements to be classified in stockholders’ equity.
 
 The
fair market value of the Pre-Funded Warrants has been estimated as the difference between the share price of our stock on the agreement
date and the exercise price of the Pre-Funded Warrant. 

 The
fair market value of the Common Warrants at their issuance has been estimated using the Black-Scholes option-pricing model. The assumed
dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. Expected volatility for
the Company’s common stock is determined based on the historical volatility of the Company over the full term of the warrant. The
risk-free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant. The expected
term of the Common Warrants was calculated utilizing the three-year expiration date, taking into consideration the possibility of an accelerated
expiration date pursuant to the terms of the Common Warrants. 

 The
estimated fair market values of the Shares, Pre-Funded Warrants and Common Warrants have been recorded in additional paid in capital.
As of June 30, 2024 no warrant has expired or has been exercised. 
 
 12 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 11 .
 Stock-Based Compensation 

 2020 Inducement Plan 

 On March 26, 2020, the Compensation
Committee of the Board of Directors, or the Compensation Committee, approved the 2020 Inducement Plan in order to award nonstatutory stock
options, restricted stock awards, restricted stock unit awards and other stock-based awards to persons not previously an employee or director
of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment
with the Company.

 The total number of shares
authorized under the 2020 Inducement Plan is 600,000 for the issuance of the Company’s common stock. The Compensation Committee
also adopted a form of stock option grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted
stock unit agreement for use with the Inducement Plan.

 As of June 30, 2024,
there were 526,597 shares of common stock subject to outstanding awards and 73,403 shares of common stock available for future issuance
under the 2020 Inducement Plan. 

 2017 Equity Incentive Plan 

 On August 10, 2017, Private
ArTara (a predecessor entity of the Company), its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017
Equity Incentive Plan to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize
personnel for productivity and growth.

 The total number of shares
authorized under the 2017 Equity Incentive Plan was 2,000,000 for the issuance of stock options, stock appreciation rights, restricted
stock and restricted stock units to among others, members of the Board of Directors, employees, consultants and service providers to the
Company and its affiliates. As of January 9, 2020, no additional awards will be made under the 2017 Equity Incentive Plan.

 2014 Equity Incentive Plan 

 On October 3, 2014, the stockholders
approved the 2014 Equity Incentive Plan. On June 20, 2017, the Company’s Board of Directors amended the 2014 Equity Incentive Plan,
or the Amended and Restated 2014 Plan. On July 31, 2017, the stockholders approved this amendment. On January 1, 2020, Protara Therapeutics,
Inc. amended its Amended and Restated 2014 Equity Incentive Plan.

 The Amended and Restated
2014 Plan, as amended, provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock
and stock unit awards, performance units, stock grants and qualified performance-based awards. The Amended and Restated 2014 Plan, as
amended, provides that the number of shares reserved and available for issuance will automatically increase each January 1, by four percent
of the Company’s common stock on the immediately preceding December 31, adjusted for the number of shares of the Company’s
common stock issuable upon conversion of any security that the Company may issue that is convertible into or exchangeable for the Company’s
common stock, or such lesser number of shares as determined by the Company’s Board of Directors. Terms of the stock awards, including
vesting requirements, are determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated
vesting if there is a change in control as defined in the plan.
 
 13 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 On January 1, 2024, pursuant
to the annual evergreen feature of the Amended and Restated 2014 Plan, as amended, the number of shares authorized under the Amended and
Restated 2014 Plan, as amended, was increased by 911,380 shares to 4,474,683 shares. As of June 30, 2024, there were 3,776,050 shares
of common stock subject to outstanding awards. Following the approval of the Company’s 2024 Equity Incentive Plan, or 2024 EIP,
by the stockholders of the Company on June 7, 2024, no additional awards will be made under the 2014 Equity Incentive Plan.

 2024 Equity Incentive
Plan 

 On June 7, 2024, the stockholders
approved the 2024 EIP. The 2024 EIP provides for the grant of 1,500,000 shares of common stock for stock options, stock appreciation rights,
restricted stock, restricted stock units, performance units, performance shares and other stock and cash awards.

 Terms of the stock awards,
including vesting requirements, are determined by the Board of Directors, subject to the provisions of the plan.

 As of June 30, 2024, there
were 0 shares of common stock subject to outstanding awards and 1,500,000 shares of common stock available for future issuance under the
2024 EIP.

 2024 Employee Stock
Purchase Plan 

 On June 7, 2024, the stockholders
of the Company approved the 2024 Employee Stock Purchase Plan, or 2024 ESPP. The number of shares authorized under the 2024 ESPP is 1,000,000 .

 As of June 30, 2024, the
number of shares available for issuance was 1,000,000 . During the three and six months ended June 30, 2024, no shares were issued under
the 2024 ESPP. 

 Restricted Stock Units 

 The following table summarizes
restricted stock unit, or RSU, activities for the six months ended June 30, 2024: 

 Restricted
 Stock 
 Units 
 Weighted
 Average
 Grant
 Date Fair
 Value 

 Non-vested as of December 31, 2023 
 236,679 
 $ 7.07 

 Granted 
 210,700 
 1.91 

 Forfeited 
 ( 39,886 ) 
 2.89 

 Vested 
 ( 111,579 ) 
 10.45 

 Non-vested as of June 30, 2024 
 295,914 
 $ 2.69 

 The fair value of RSUs is amortized
on a straight-line basis over the requisite service period of the respective awards. As of June 30, 2024, the unamortized value of RSUs
was $ 594 . As of June 30, 2024, the weighted average remaining amortization period was 2.09 years. As of June 30, 2024 and December 31,
2023, 289,500 RSUs have vested that have not yet been settled into shares of the Company’s common stock.

 During the six months ended
June 30, 2024, the Company issued 73,909 shares of the Company’s common stock from the net settlement of 111,579 RSUs. The Company
paid $ 83 in connection with the net share settlement of these RSUs.
 
 14 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 Stock Options 

 The following table summarizes
stock option activities for the six months ended June 30, 2024: 

 Options Weighted
 Average
 Exercise
 Price Weighted
 Average
 Remaining
 Contractual
 Term
 (years) Aggregate
 Intrinsic
 Value (1) 
 Outstanding as of December 31, 2023 2,900,205 $ 9.50 8.03 $ 20 
 Granted 1,301,700 1.99 - - 
 Exercised ( 47,580 ) 2.83 - 23 
 Forfeited ( 302,137 ) 3.14 - - 
 Expired ( 627 ) 3.20 - - 
 Outstanding as of June 30, 2024 3,851,561 $ 7.54 7.95 $ 167 
 
 Vested and expected to vest at June 30, 2024 3,851,561 $ 7.54 7.95 $ 167 
 Exercisable as of June 30, 2024 1,769,285 12.63 6.70 -
 
 (1) Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December 31, 2023 and June 30, 2024, respectively. The intrinsic value of options exercised during the six months ended June 30, 2024 was $ 23 and 47,580 options were exercised. 
 
 The weighted average grant
date fair value per share of the options granted during the six months ended June 30, 2024 and 2023 was $ 1.58 and $ 2.40 respectively.
As of June 30, 2024, there was approximately $ 4,980 of unrecognized share-based compensation for unvested stock option grants, which is
expected to be recognized over a weighted average period of 2.72 years. The total unrecognized stock-based compensation cost will be adjusted
for actual forfeitures as they occur.

 Summary of Stock-Based Compensation Expense 

 The following tables summarize
total stock-based compensation costs recognized: 

 For the 
 Three Months Ended 
 June 30, 
 
 For the 
 Six Months Ended 
 June 30, 
 
 2024 
 2023 
 2024 
 2023 

 Restricted stock units 
 $ 111 
 $ 326 
 $ 262 
 $ 640 

 Stock options 
 953 
 1,292 
 2,028 
 2,553 

 Total 
 $ 1,064 
 $ 1,618 
 $ 2,290 
 $ 3,193 

 Stock-based compensation
expense was reflected within the condensed consolidated statements of operations and comprehensive loss as: 

 For the 
 Three Months ended 
 June 30, 
 
 For the 
 Six Months Ended 
 June 30, 
 
 2024 
 2023 
 2024 
 2023 

 Research and development 
 $ 237 
 $ 414 
 $ 611 
 $ 814 

 General and administrative 
 827 
 1,204 
 1,679 
 2,379 

 Total 
 $ 1,064 
 $ 1,618 
 $ 2,290 
 $ 3,193 

 15 

 Protara Therapeutics, Inc. and Subsidiaries 
 
 Notes to Unaudited Condensed Consolidated Financial
Statements 
 
 (amounts
in thousands, except share and per share data) 
 
 12.
Net Income (Loss) per Common Share 

 The following table sets
forth the computation of the net income (loss) per share attributable to common stockholders, basic and diluted: 

 For the 
 Three Months ended 
 June 30, 
 
 For the 
 Six Months Ended 
 June 30, 
 
 2024 
 2023 
 2024 
 2023 

 Numerator 
 
 Net income (loss) attributable to common stockholders 
 $ ( 9,513 ) 
 $ ( 11,294 ) 
 $ ( 20,608 ) 
 $ ( 20,339 ) 

 Denominator 
 
 Weighted-average shares of common stock outstanding, basic and diluted
 
 21,233,163 
 11,307,842 
 16,327,056 
 11,305,867 

 Net income (loss) per share attributable to common stockholders, basic and diluted
 
 $ ( 0.45 ) 
 $ ( 1.00 ) 
 $ ( 1.26 ) 
 $ ( 1.80 ) 

 The Pre-Funded Warrants for
the purchase of 1,700,000 shares of common stock with an exercise price of $ 0.001 per share have been included in the computation of the
net loss per share attributable to common stockholders – basic and diluted, as the exercise price was deemed non-substantive. 

 Since the Company was in a net loss position for all periods presented,
net income (loss) per share attributable to common stockholders was the same, on a basic and diluted basis, as the inclusion of all potential
common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential shares of common stock,
presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to
common stockholders for the periods indicated because including them would have had an anti-dilutive effect: 

 As of 
 June 30, 

 2024 
 2023 

 Stock options issued and outstanding 
 3,851,561 
 3,074,128 

 Restricted stock units issued and outstanding 
 585,414 
 584,852 

 Series 1 Convertible Preferred Stock issued and outstanding 
 7,993,217 
 8,029,039 

 Common Warrants, issued and outstanding 
 10,843,380 
 -
 
 Total potentially dilutive shares 
 23,273,572 
 11,688,019 

 16 

 Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations 
 
 You should read the following
discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial
statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. 
 
 Our actual results and
timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking
statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations,
financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking
statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity,
and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly
Report on Form 10-Q, they may not be predictive of results or developments in future periods. 
 
 Overview 
 
 We are a New York City based
clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases.
We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in
order to create new development opportunities. We prioritize creativity, diverse perspectives, integrity and tenacity to expedite our
goal of bringing life-changing therapies to people with limited treatment options.
 
 Our portfolio includes two
development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally
granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. This cell
therapy is currently approved in Japan and Taiwan for lymphatic malformations, or LMs, and multiple oncologic indications. We have secured
worldwide rights to the asset excluding Japan and Taiwan and are exploring its use in oncology and rare disease indications. TARA-002
was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil®
in Japan and Taiwan by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical). We are currently developing TARA-002 in non-muscle
invasive bladder cancer, or NMIBC, and in LMs.
 
 Our lead oncology program
is TARA-002 in NMIBC, which is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder
muscle. Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer
diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. Very few new therapeutics have been
approved for NMIBC since the 1990s and the current standard of care for NMIBC includes intravesical Bacillus Calmette–Guérin,
or BCG. The mechanism of action of TARA-002 is similar in some ways to that of BCG. TARA-002 and BCG are both intravesically administered,
elicit a Th1 type immune response and produce a generally similar array of locally activated cytokines and immune cells.
 
 We are conducting a Phase
1 open-label clinical trial to evaluate TARA-002 in treatment-naïve and treatment-experienced NMIBC patients with carcinoma in situ,
or CIS, and high-grade papillary tumors, or Ta, known as the ADVANCED-1 trial. In the initial dose escalation phase of the trial, patients
received six weekly intravesical doses of TARA-002, evaluating the 10KE, 20KE and 40KE doses (Klinische Einheit, or KE, is a German term
indicating a specified weight of dried cells in vial). The primary objective of the trial is to evaluate the safety, tolerability and
preliminary signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended Phase 2 dose. In April 2023, we announced
positive preliminary data from the Phase 1a dose escalation component of the ongoing ADVANCED-1 trial through the 40KE dose, in which
TARA-002 indicated favorable tolerability and anti-tumor activity in NMIBC patients. A maximum tolerated dose was not determined,
and dose escalation at the 80KE dose remains ongoing in an exploratory cohort.
 
 17 

 Preliminary data from the ADVANCED-1 trial suggested that intravesical
TARA-002 was generally well tolerated at the three dose levels evaluated in the initial phase of the trial (10KE, 20KE, and 40KE), and
no dose limiting toxicities were observed. The Company has selected the 40KE dose for use in subsequent clinical trials. The majority
of reported adverse events were Grades 1 and 2 across all dose levels, and treatment emergent adverse events, or TEAEs, as assessed by
study investigators, were in line with typical responses to bacterial immunopotentiation and included fatigue, headache, fever and chills.
The most common urinary symptoms were urinary urgency, urinary frequency, urinary tract pain/burning, incomplete emptying, and bladder
spasm. Most bladder irritations resolved soon after administration, or in a few hours to a few days. A total of nine patients were enrolled
in the dose escalation portion of the study through the 40KE dose. Of those, three patients with CIS, one of whom was a heavily pre-treated
BCG-unresponsive patient, achieved a complete response, or CR, at the 20KE dose, and tumor regression was observed in the other two patients.
Results from six patients with high-grade, non-invasive papillary, or HGTa, tumors showed five of six patients with high-grade recurrence
free survival, or HGRFS, at week 12. The patient who did not achieve HGRFS was dosed at 10KE, the lowest dose of TARA-002 offered in the
trial.
 
 The ongoing open-label expansion trial, or ADVANCED-1EXP, is evaluating
intravesical TARA-002 at the 40KE dose in up to 12 CIS patients, including BCG-naïve, BCG-unresponsive, and BCG-inadequately treated
patients. In April 2024, we announced positive data from three-month evaluable NMIBC patients with CIS pooled across our clinical studies,
including ADVANCED-1 Phase 1a, ADVANCED-1 EXP Phase 1b and ADVANCED-2 Phase 2 trials of TARA-002 in patients with high-risk NMIBC, including
BCG-Unresponsive, BCG-Experienced and BCG-Naïve patients. The overall three-month CR rate prior to reinduction for the 16 evaluable
patients was 38%, with a CR rate of 63% in CIS-only patients and 13% in patients with CIS +Ta/T1 (T1 is defined as carcinoma invading
the lamina propria). A 43% CR rate was observed in BCG-Unresponsive/Experienced patients. TARA-002 demonstrated a favorable safety and
tolerability profile. The majority of reported adverse events were Grades 1 and 2 across all dose levels, and there were no Grade 3 or
higher TEAEs. TEAEs as assessed by study investigators, were in line with typical responses to bacterial immunopotentiation, and included
fatigue, headache, fever, and chills. The most common urinary symptoms were urinary urgency, urinary frequency, urinary tract pain/burning,
incomplete emptying, and bladder spasm. Most bladder irritations resolved in a few hours to a few days. Additional details regarding the
data, which support the potential for TARA-002 in treating high risk patients can be found in the following table:
 
 Three Month Evaluable Patients 

 # Patients 
 # of CRs 
 CR % 

 BCG-Unresponsive/ Experienced 
 
 CIS-only 
 6 
 3 
 50 % 

 CIS +Ta/T1 
 1 
 - 
 - % 

 7 
 3 
 43 % 

 BCG-Naïve 
 
 CIS-only 
 2 
 2 
 100 % 

 CIS +Ta/T1 
 7 
 1 
 14 % 

 9 
 3 
 33 % 

 16 
 6 
 38 % 

 By Stage of Disease at Baseline 
 
 CIS-only 
 8 
 5 
 63 % 

 CIS +Ta/T1 
 8 
 1 
 13 % 

 16 
 6 
 38 % 

 By Study 
 
 Phase 1a 
 3 
 1 
 33 % 

 Phase 1b-EXP 
 8 
 3 
 38 % 

 Phase 2 Naïve 
 5 
 2 
 40 % 

 16 
 6 
 38 % 

 Data cutoff date: March 19, 2024
 
 18 

 We expect to share preliminary
results from a pre-planned risk-benefit analysis of the ongoing Phase 2 open-label ADVANCED-2 trial in the fourth quarter of 2024. The
analysis is expected to include approximately 10 patients who are six-month evaluable. The ongoing ADVANCED-2 trial is assessing intravesical
TARA-002 in NMIBC patients with CIS (± Ta/T1) who are BCG-Naïve (n=27) and BCG-Unresponsive (n≈100). The BCG-Unresponsive
cohort has been designed to be registrational aligned with the United States Food and Drug Administration’s, or FDA’s, 2018
BCG-Unresponsive Non-muscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry. Trial subjects
will receive an induction course of six weekly intravesical instillations, and following mandatory biopsy at three months, will either
receive a reinduction course of six weekly intravesical instillations of TARA-002, or the first maintenance course of three weekly installations
every three months, for an additional 12 months.
 
 In addition to the ADVANCED-2
trial, we will continue to explore higher dosing at an 80KE dose and systemic priming prior to initiation of intravesical administration,
in each case to assess the anti-tumor activity of TARA-002. We continue to believe that combination therapy may play a meaningful role
in the NMIBC treatment paradigm and intend to prioritize trials assessing TARA-002 in combination with other therapies. Given TARA-002’s
mechanism of action and safety profile, we believe it has strong potential as a combination agent and we continue to evaluate the best
potential combination therapy options for our clinical program.
 
 In addition, we continue
to conduct non-clinical studies on TARA-002 to better characterize the mechanism of action to help us understand how TARA-002 may perform
in potential combinations with other agents used to treat NMIBC. We use non-clinical data to help us define other cancer targets for TARA-002,
both within urothelial cancer and other types of cancer affecting different parts of the body.
 
 We are also pursuing intravenous,
or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral nutrition, or
PN. Choline is a known important substrate for phospholipids that are critical for healthy liver function and also plays an important
role in modulating gene expression, cell membrane signaling, brain development and neurotransmission, muscle function, and bone health.
PN patients are unable to synthesize choline from enteral nutrition sources, and there are currently no available PN formulations containing
choline. Approximately 80 percent of PN-dependent patients are choline-deficient and have some degree of liver damage, which can lead
to hepatic failure. There are currently no available PN formulations containing choline. In the U.S. alone, there are approximately 40,000
patients on long-term PN who would benefit from an IV formulation of choline. IV Choline Chloride has the potential to become the first
FDA approved IV choline formulation for PN patients.
 
 Choline is recommended for
patients on PN by the American Society for Parenteral and Enteral Nutrition, or ASPEN, in their Recommendations for Changes in Commercially
Available Parenteral Multivitamin and Multi–Trace Element Products, as well as by the European Society for Clinical Nutrition and
Metabolism, or ESPEN, in their Guideline on Home Parenteral Nutrition. IV Choline Chloride has been granted Orphan Drug Designation by
the FDA for the prevention of choline deficiency in PN patients. We have been issued a U.S. patent by the U.S. Patent and Trademark Office
claiming a choline composition with a term expiring in 2041.
 
 In April 2024, we announced
alignment with the FDA on a registrational path forward for IV Choline Chloride in patients dependent on PN. Previously, we had been pursuing
an indication in intestinal failure-associated liver disease, or IFALD, and following feedback from the FDA, are pursuing a broader indication
in patients on PN who are or may become unable to synthesize choline from oral or enteral nutrition sources. Feedback from the FDA on
our IV Choline Chloride program indicated that a single study with an endpoint of restoring choline levels in PN patients could serve
as the basis for a regulatory filing for IV Choline Chloride. We plan to advance the development of IV Choline Chloride as a source of
choline for adult and adolescent patients on long-term PN and intend to initiate a registrational Phase 3 trial in the first quarter of
2025.
 
 We are also pursuing TARA-002
in LMs, which are rare, non-malignant cysts of the lymphatic vascular system that primarily form in the head and neck region of children
before the age of two. In July 2020, the FDA granted Rare Pediatric Disease designation for TARA-002 for the treatment of LMs and in May
2022 the European Medicines Agency granted orphan drug designation to TARA-002 for the treatment of LMs. In addition to the clinical experience
in Japan, we have secured the rights to a dataset from one of the largest ever conducted Phase 2 trials in LMs, in which OK-432 was administered
via a compassionate use program led by the University of Iowa to over 500 pediatric and adult patients. We have an investigational new
drug application for LMs with the Vaccines and Related Products Division of the FDA, or Vaccines Division.
 
 19 

 In October 2023, we initiated
STARBORN-1, which is a Phase 2 single-arm, open-label, prospective clinical trial to evaluate the safety and efficacy of intracystic injection
of TARA-002 for the treatment of macrocystic and mixed-cystic LMs (≥ 50% macrocystic disease) in participants six months to less than
18 years of age. Including an age de-escalation safety lead-in, the trial will enroll approximately 30 patients who will receive up to
four injections of TARA-002 spaced approximately six weeks apart.
 
 The primary endpoint of the
trial is the proportion of participants with macrocystic LMs and mixed-cystic LMs who demonstrated clinical success, defined as having
either a complete response (90% to 100% reduction from baseline in total LM volume) or substantial response (60% to less than 90% reduction
in total LM volume) as measured by axial imaging. We have completed enrollment in the first 3-patient safety cohort and plan to begin
enrolling the second safety cohort shortly.
 
 We believe TARA-002 may also have the potential to be used to
treat other maxillofacial cysts based on the historical literature from the TARA-002 predecessor, OK-432, as well as recent data in one
pediatric patient with a maxillofacial cyst called a Ranula, which resolved nearly 100% after a single 1KE dose of TARA-002. While
completing STARBORN-1 in LMs is our priority, we believe there may be an opportunity in the future to explore the potential of TARA-002
to treat different types of maxillofacial cysts. 
 
 We have devoted substantial
efforts to the development of these programs and do not have any approved products and have not generated any revenue from product sales.
Neither TARA-002 nor IV Choline Chloride have been approved for use for any indications. We do not expect to generate revenues in the
near-term, and it is possible we may never generate revenues in the future. To finance our current strategic plans, including the conduct
of ongoing and future clinical trials and further research and development costs, we will need to raise additional capital. See “—Liquidity
and Capital Resources” for additional information about our liquidity and capital resource needs.
 
 Since inception, we have
incurred significant operating losses. As of June 30, 2024, we had an accumulated deficit of approximately $221.0 million. We expect to
continue to incur significant and increasing expenses and operating losses for at least the next few years as we continue our development
of, and seek marketing approvals for, our product candidates, prepare for and begin the commercialization of any approved products, and
add infrastructure and personnel to support our product development efforts and operations as a public company in the United States.
 
 As a clinical-stage company,
our expenses and results of operations are likely to fluctuate significantly from quarter-to-quarter and year-to-year. We believe that
our period-to-period comparisons of our results of operations should not be relied upon as indicative of our future performance.
 
 As of June 30, 2024, we had approximately $89.6 million in cash,
cash equivalents, and marketable debt securities. On April 10, 2024, we completed a private placement, or the 2024 Private Placement,
pursuant to which we sold 9,143,380 shares of our common stock, or the Shares, and, for certain purchasers, pre-funded warrants, or the
Pre-Funded Warrants, to purchase an aggregate of 1,700,000 shares of our common stock. In each case, the Shares and Pre-Funded Warrants
were accompanied by common warrants, or the Common Warrants, to purchase an aggregate of up to 10,843,380 shares of common stock at a
price of $5.25. Each Share, along with its attached Common Warrant, has a purchase price of $4.15, and each Pre-Funded Warrant, along
with its attached Common Warrant, has a purchase price of $4.149. We received gross proceeds of
approximately $45.0 million and net proceeds of approximately $42.0 million, reflecting approximately $3.0 million of placement
agent’s fees, legal costs and other expenses in connection with the transaction. 
 
 Financial Overview 
 
 Research
and Development 
 
 Research and development
expenses consist primarily of costs incurred for the development of TARA-002 and IV Choline Chloride, which include personnel-related
expenses, including salaries, benefits, travel and stock-based compensation expense, expenses incurred under agreements with clinical
research organizations, or CROs, contract development and manufacturing organizations, or CDMOs, the cost of acquiring, developing and
manufacturing clinical trial materials, clinical and non-clinical related costs, costs associated with regulatory operations and facilities,
depreciation and other expenses, which include expenses for rent and maintenance of facilities and other supplies.
 
 20 

 General and Administrative 
 
 General and administrative
expenses consist principally of personnel-related expenses, including salaries, benefits, travel and stock-based compensation expense,
in executive and other administrative functions. Other general and administrative expenses also include professional fees for legal, intellectual
property matters, consulting and accounting services, facility related costs, as well as expenses related to audit, legal, regulatory
and tax-related services associated with maintaining compliance with our Nasdaq listing and SEC requirements, director and officer liability
insurance premiums and investor relations costs associated with being a public company.
 
 Other Income
(Expense), net 
 
 Interest and investment income
consists of interest and dividend income on our cash, cash equivalents and marketable debt securities and amortization of premiums and/or
accretion of discounts.
 
 Critical Accounting Policies and Significant
Judgments and Estimates 
 
 Our management’s discussion
and analysis of our financial position and results of operations is based on our financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States of America, or GAAP. The preparation of financial statements in conformity
with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying
notes. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable
under the circumstances. Actual results may differ materially from those estimates or assumptions.
 
 Our critical accounting policy
is the accounting for accrued research and development expenses. We record accruals for estimated costs of research, preclinical, clinical
and manufacturing development within accrued expenses which are significant components of research and development expenses. A substantial
portion of our ongoing research and development activities are conducted by third-party service providers. We accrue costs incurred under
these third-party arrangements based on estimates of actual work completed in accordance with the respective agreements. We determine
the estimated costs to accrue through discussions with internal personnel and our external service providers as to the percentage of completion
of the services and the agreed-upon fees to be paid for such services. Payments made to third parties under these arrangements in advance
of performance of the related services are recorded as prepaid expenses until the services are rendered.
 
 It is important that the
discussion of our operating results that follow be read in conjunction with these critical accounting policies which have been disclosed
in our Annual Report on Form 10-K filed with the SEC on March 13, 2024.
 
 Results of Operations 
 
 Comparison of the Three Months Ended June
30, 2024 and 2023 
 
 The following table summarizes
our results of operations for the three months ended June 30, 2024 and 2023 (in thousands):
 
 For The 
 Three Months Ended
 June 30, 
 Period-to-
 Period 

 2024 
 2023 
 Change 

 Operating expenses: 
 
 Research and development 
 $ 6,387 
 $ 7,247 
 $ (860 ) 

 General and administrative 
 4,274 
 4,893 
 (619 ) 

 Total operating expenses 
 10,661 
 12,140 
 (1,479 ) 

 Loss from operations 
 (10,661 ) 
 (12,140 ) 
 1,479 

 Other income (expense), net: 
 
 Interest and investment income 
 1,148 
 846 
 302 

 Other income (expense), net 
 1,148 
 846 
 302 

 Net income (loss) 
 $ (9,513 ) 
 $ (11,294 ) 
 $ 1,781 

 21 

 Research and development
expenses. During the three months ended June 30, 2024, our research and development expenses were approximately $6.4 million, which
represented a decrease of approximately $0.9 million as compared to the three months ended June 30, 2023. This decrease was primarily
due to an $0.8 million decrease in expenses related to TARA-002, inclusive of $0.6 million in non-clinical activities and $0.2 million
in clinical trial activities.
 
 General and administrative
expenses. During the three months ended June 30, 2024, our general and administrative expenses were approximately $4.3 million, which
represented a decrease of approximately $0.6 million as compared to the three months ended June 30, 2023. This decrease was primarily
due to a reduction of $0.4 million in personnel-related expenses associated with stock-based compensation as well as a decrease in market
development activities of $0.4 million offset slightly by an increase in legal activities of $0.1 million.
 
 Other income (expense),
net . During the three months ended June 30, 2024, our other income (expense), net was approximately $1.1 million, which represented
an increase of approximately $0.3 million as compared to the three months ended June 30, 2023, due primarily to higher market interest
rates obtained from money market funds on a higher invested balance. 
 
 Comparison of the Six Months Ended June
30, 2024 and 2023 
 
 The following table summarizes
our results of operations for the six months ended June 30, 2024 and 2023 (in thousands):
 
 For The 
 Six Months Ended
 June 30, 
 Period-to-
 Period 

 2024 
 2023 
 Change 

 Operating expenses: 
 
 Research and development 
 $ 14,135 
 $ 12,390 
 $ 1,745 

 General and administrative 
 8,377 
 9,482 
 (1,105 ) 

 Total operating expenses 
 22,512 
 21,872 
 640 

 Loss from operations 
 (22,512 ) 
 (21,872 ) 
 (640 ) 

 Other income (expense), net: 
 
 Interest and investment income 
 1,904 
 1,533 
 371 

 Other income (expense), net 
 1,904 
 1,533 
 371 

 Net income (loss) 
 $ (20,608 ) 
 $ (20,339 ) 
 $ (269 ) 

 Research and development
expenses . During the six months ended June 30, 2024, our research and development expenses were approximately $14.1 million, which
represented an increase of approximately $1.7 million as compared to the six months ended June 30, 2023. This increase was primarily due
to an increase in personnel-related expenses of $1.1 million and an $0.8 million increase in costs associated to the TARA-002 program,
consisting of a $1.7 million increase in clinical trial activities offset by a $1.0 million reduction in non-clinical activities. This
was partially offset by a reduction in expenses of $0.2 million in clinical trial activities associated with IV Choline due to the completion
of the prevalence study.
 
 General and administrative
expenses. During the six months ended June 30, 2024, our general and administrative expenses were approximately $8.4 million, which
represented a decrease of approximately $1.1 million as compared to the six months ended June 30, 2023. This decrease was primarily due
to a reduction of $0.9 million in personnel-related expenses (inclusive of $0.7 million of stock-based compensation).
 
 Other income (expense),
net . During the six months ended June 30, 2024, our other income (expense), net was approximately $1.9 million, which represented
an increase of approximately $0.4 million as compared to the six months ended June 30, 2023, due primarily to higher market interest rates
obtained from money market funds on a higher invested balance. 
 
 22 

 Liquidity and Capital Resources 
 
 Overview 
 
 As of June 30, 2024 and December
31, 2023, our cash, cash equivalents, and marketable debt securities were $89.6 million and $65.6 million, respectively. We have not generated
revenues since our inception and have incurred net losses of $20.6 million and $20.3 million for the six months ended June 30, 2024 and
2023, respectively, and $9.5 million and $11.3 million for the three months ended June 30, 2024 and 2023 respectively. As of June 30,
2024, we had working capital of $86.6 million and stockholder’s equity of $92.0 million. During the six months ended June 30, 2024,
net cash flows used in operating activities were $18.1 million, consisting primarily of a net loss of $20.6 million including non-cash
expenses of $2.9 million, as well as working capital adjustments of $0.3 million. Since inception, we have met our liquidity requirements
principally through the sale of our common stock and preferred stock in private placements. More recently, on April 10, 2024, we completed
our 2024 Private Placement, pursuant to which we sold 9,143,380 Shares, and, for certain purchasers, Pre-Funded Warrants to purchase an
aggregate of 1,700,000 shares of common stock. In each case, the shares and Pre-Funded Warrants were accompanied by Common Warrants to
purchase an aggregate of up to 10,843,380 shares of common stock at a price of $5.25. We received total net proceeds of approximately
$42.0 million after deducting placement agent fees and offering expenses.
 
 We are in the business of
developing biopharmaceuticals and have no current or near-term revenues. We have incurred substantial clinical and other costs in our
drug development efforts. We will need to raise additional capital in order to fully realize management’s plans. 
 
 We believe that our current
financial resources, as of the date of the issuance of our condensed consolidated financial statements included elsewhere in this Quarterly
Report on Form 10-Q, are sufficient to satisfy our estimated liquidity needs for at least twelve months from the date of filing this quarterly
report on Form 10-Q.
 
 As a result of volatility
in the capital markets, economic conditions, general global economic uncertainty, political change, global pandemics, and other factors,
we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital
on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty
or other factors, we may need to curtail planned development activities. Specifically, higher, and potentially increasing interest rates
could impact our access to capital, and could in the future negatively affect our liquidity. A recession or market correction, continued
supply chain disruptions and/or inflation could materially affect our business and the value of our common stock. Further, recent rises
in interest rates have had, and may continue to have, a negative effect on market prices for common stock of public companies, especially
those in the pharmaceutical industry and those that have no current or near-term revenue.
 
 Cash Flows 
 
 The following table summarizes
our sources and uses of cash for the six months ended June 30, 2024 and 2023 (in thousands):
 
 For The Six Months Ended
 June 30, 
 Period-to-
 Period 

 2024 
 2023 
 Change 

 Net cash provided by (used in) operating activities 
 $ (18,066 ) 
 $ (22,296 ) 
 $ 4,230 

 Net cash provided by (used in) investing activities 
 26,045 
 32,211 
 (6,166 ) 

 Net cash provided by (used in) financing activities 
 42,016 
 (64 ) 
 42,080 

 Net increase (decrease) in cash and cash equivalents, and restricted cash 
 $ 49,995 
 $ 9,851 
 $ 40,144 

 23 

 Comparison of the Six Months Ended June
30, 2024 and 2023 
 
 Net cash used in operating activities was $18.1 million for the
six months ended June 30, 2024 compared to $22.3 million for the six months ended June 30, 2023. The decrease of $4.2 million in cash
used in operating activities was primarily driven by a $5.4 million decrease in working capital adjustments, primarily related to changes
in prepaid expenses and other current assets, and accrued expenses resulting from the timing of payments to our service providers offset
partially by an increase in net loss of $0.3 million which includes a $1.0 million decrease in non-cash items including stock-based compensation,
operating lease right-of-use asset, depreciation, and amortization of premium on marketable debt securities.
 
 Net cash provided by investing
activities was $26.0 million for the six months ended June 30, 2024 compared to $32.2 million for the six months ended June 30, 2023.
The decrease of $6.2 million resulted primarily from the maturation of marketable debt securities, the proceeds of which went into money
market funds.
 
 Net cash provided by/(used in) financing activities was approximately
$42.0 million and $0.1 million for the six months ended June 30, 2024 and 2023, respectively. The increase of $40.1 million resulted primarily
from the net proceeds of the 2024 Private Placement transaction, which took place in April 2024.
 
 Contractual and Other Obligations 
 
 Operating lease obligations 
 
 Our operating lease obligations
primarily consist of lease payments on our corporate headquarters in New York, New York, as well as lease payments for our development
laboratory, a manufacturing facility and an additional manufacturing space, all located in North America which are described in further
detail in Note 8 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. 
 
 Other obligations 
 
 From time to time, we enter
into certain types of contracts that contingently require us to indemnify parties against third-party claims, supply agreements, and agreements
with directors and officers. The terms of such obligations vary by contract and in most instances a maximum dollar amount is not explicitly
stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted, thus no liabilities
have been recorded for these obligations on our condensed consolidated balance sheet for the periods presented.
 
 We enter into contracts in
the normal course of business with CROs, CDMOs, and clinical sites for the conduct of clinical trials, non-clinical research studies,
professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts generally
provide for termination on notice, and therefore are cancelable contracts.
 
 Certain of these agreements
require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones as further
described in Note 9 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. Amounts related
to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain
development, regulatory approval and commercial milestones, which may not be achieved.
 
 We also have obligations
to make future payments to third parties that become due and payable on the achievement of certain milestones, including future payments
to third parties with whom we have entered into research, development and commercialization agreements. We have not included these commitments
on our condensed consolidated balance sheet for the periods presented because the achievement and timing of these milestones is not fixed
and determinable.
 
 24 

 Off-Balance Sheet Arrangements 
 
 We did not have, during the
periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the applicable regulations of the
SEC.
 
 Item 3. Qualitative and Quantitative Disclosures
about Market Risk 
 
 Not applicable.
 
 Item 4. Controls and Procedures 
 
 Management’s Evaluation of our Disclosure
Controls and Procedures 
 
 We maintain disclosure controls
and procedures, as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed
to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed,
summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to
our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding
required disclosure.
 
 As of June 30, 2024, our
management, with the participation of our principal executive and principal financial officer, evaluated the effectiveness of our disclosure
controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Our management recognizes that any
controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives,
and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal
executive and principal financial officer have concluded based upon the evaluation described above that, as of June 30, 2024, our disclosure
controls and procedures were effective at the reasonable assurance level.
 
 We continue to review and
document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may from
time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.
 
 Changes in Internal Control Over Financial
Reporting 
 
 There were no changes in
our internal control over financial reporting during the quarter ended June 30, 2024, as such term is defined in Rules 13a-15(f) and 15(d)-15(f)
promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.
 
 25 

 PART II – OTHER INFORMATION 
 
 Item 1. Legal Proceedings 
 
 From time to time, we may
be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently
a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources
and other factors.
 
 Item 1A. Risk Factors 
 
 There
were no material changes to the risk factors previously disclosed in “Part II, Item 1A—Risk Factors” of our Annual Report
on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 13, 2024 and “Part II, Item 1A —Risk Factors”
of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 2, 2024.
 
 Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds 
 
 On
April 5, 2024, the Company entered into a subscription agreement with certain purchasers, or the Purchasers, pursuant to which
the Company agreed to sell and issue to the Purchasers, in a private placement, or the 2024 Private Placement, an aggregate of 9,143,380
shares of the Company’s common stock, or the Shares, held by certain selling stockholders, and, for certain purchasers, pre-funded
warrants, or the Pre-Funded Warrants, to purchase an aggregate of 1,700,000 shares of the Company’s common stock. In each case,
the Shares or Pre-Funded Warrants were issued with warrants or the Common Warrants, to purchase an aggregate of up to 10,843,380 shares
of the Company’s common stock. Each Share, along with its attached Common Warrant, has a purchase price of $4.15, and each Pre-Funded
Warrant, along with its attached Common Warrant, has a purchase price of $4.149. The closing date of the 2024 Private Placement was April
10, 2024. The 2024 Private Placement resulted in gross proceeds of approximately $45.0 million
and net proceeds of approximately $42.0 million, reflecting approximately $3.0 million of placement agent’s fees, legal costs
and other expenses connected with the transaction. The Company intends to use the net proceeds from the 2024 Private Placement
for general corporate and working capital purposes, including funding clinical trials. General corporate and working capital purposes
may include clinical study expenditures such as the addition of an 80 KE (Klinische Einheit, or KE, is a German term indicating a specified
weight of dried cells in vial) dose cohort and a systemic priming cohort to the ongoing ADVANCED-2 Phase 2 clinical trial of the
Company’s product candidate intravesical TARA-002 in patients with high-risk Non-Muscle Invasive Bladder Cancer (“NMIBC”)),
manufacturing expenditures, commercialization expenditures and capital expenditures. Guggenheim Securities, LLC acted as lead placement
agent and Oppenheimer & Co. acted as a placement agent in the transaction. The securities sold in the 2024 Private Placement were
issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.
 
 The Pre-Funded Warrants are
exercisable at any time after April 10, 2024, at an exercise price of $0.001 per share. The Common Warrants are exercisable at any time
after April 10, 2024 and on or prior to the earlier of (i) April 10, 2027 and (ii) 90 days after the public announcement that the Company
has demonstrated a six-month complete response rate of minimum 42% from at least 25 Bacillus Calmette-Guérin (BCG)-Unresponsive
patients in the ADVANCED-2 (Cohort B) clinical trial, at an exercise price of $5.25 per share.
 
 The Pre-Funded Warrants and
the Common Warrants are exercisable so long as the aggregate number of shares of the Company’s common stock beneficially owned by
the holder (together with its affiliates) would not exceed 4.99% of the number of shares of the Company’s common stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such Pre-Funded
Warrant or Common Warrant, as applicable. Such percentage may be increased or decreased to any number not in excess of 19.99% at the holder’s
election upon notice to the Company, any such increase not to take effect until the sixty-first day after notice to the Company.
 
 Item 3. Defaults Upon Senior Securities 
 
 None.
 
 Item 4. Mine Safety Disclosures 
 
 None.
 
 Item 5. Other Information 
 
 During the three months ended
June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule
10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
 
 26 

 Item 6. Exhibits 
 
 The exhibits filed as part
of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
 
 EXHIBIT INDEX 
 
 Exhibit No. 
 
 Description 

 3.1 
 
 Sixth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 27, 2014). 

 3.2 
 
 Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 10, 2020). 

 3.3 
 
 Second Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on May 13, 2020). 

 3.4 
 
 Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Non-Voting Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 10, 2020). 

 3.5 
 
 Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Non-Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on September 23, 2020). 

 3.6 
 
 Composite Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.6 to the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 8, 2023). 

 3.7 
 
 Second Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.2 of Current Report on Form 8-K, filed with the SEC on August 3, 2017). 

 4.1 
 
 Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 10, 2020). 

 4.2 
 
 Registration Rights Agreement, dated as of September 23, 2019, by and among the Registrant and the institutional investors named therein (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K, filed with the SEC on September 24, 2019). 

 10.1 
 
 Subscription Agreement, dated April 5, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 5, 2024). 

 10.2 
 
 Form of Pre-Funded Common Stock Purchase Warrant (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 5, 2024). 

 10.3 
 
 Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 5, 2024). 

 10.4 
 
 Registration Rights Agreement, dated April 5, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 5, 2024). 

 31.1* 
 
 Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. 

 27 

 31.2* 
 
 Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. 

 32.1** 
 
 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 

 99.1*† 
 
 2024 Equity Incentive Plan of the Registrant 

 99.2*† 
 
 2024 Employee Stock Purchase Plan of the Registrant 

 99.3*† 
 
 Forms of Stock Option Agreement, Stock Option Grant Notice, Restricted
Stock Unit Agreement and Restricted Stock Unit Grant Notice under the 2024 Equity Incentive Plan of the Registrant 

 101.INS* 
 
 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language (“Inline XBRL”) 

 101.SCH* 
 
 Inline XBRL Taxonomy Extension Schema Document 

 101.CAL* 
 
 Inline XBRL Taxonomy Extension Calculation Linkbase Document 

 101.DEF* 
 
 Inline XBRL Taxonomy Extension Definition Linkbase Document 

 101.LAB* 
 
 Inline XBRL Taxonomy Extension Label Linkbase Document 

 101.PRE* 
 
 Inline XBRL Taxonomy Extension Presentation Linkbase Document 

 104 
 
 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) 

 * 
 Exhibits filed herewith. 

 ** 
 Exhibits furnished herewith. 

 † 
 Indicates management contract or compensatory plan or arrangement. 

 28 

 SIGNATURES 
 
 Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
 
 PROTARA THERAPEUTICS, INC. 

 Date: August 6, 2024 
 By: 
 /s/ Jesse Shefferman 

 Jesse Shefferman 

 Chief Executive Officer 

 (Principal Executive Officer) 

 Date: August 6, 2024 
 By: 
 /s/ Patrick Fabbio 

 Patrick Fabbio 

 Chief Financial Officer 

 (Principal Financial Officer) 

 29
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.
Protara Therapeutics, Inc. 10-Q
